Case report of entrectinib associated fulminant myocarditis
European Heart Journal - Case Reports

Abstract
ROS1 tyrosine kinase inhibitors are one of the primary immunotherapies for
A 27-year-old male being treated for lung adenocarcinoma who presented new congestive heart failure 2 weeks after starting Entrectinib. He developed refractory ventricular tachycardia, cardiogenic shock with an endomyocardial biopsy that showed active lymphohistiocytic myocarditis. With antiarrhythmic therapy, heavy sedation, mechanical circulatory support, and high-dose steroids, the patient had complete resolution of symptoms and return to baseline status.
This is a rare case with a severe complication after starting Entrectinib for lung adenocarcinoma. In the literature, this is the first case of its kind presenting with myocarditis and severe heart failure after treatment with Entrectinib. This case highlights not only using cardiac imaging, and biopsy to help guide the diagnosis, but also describe the appropriate management.
Contributors

Gohar Rundhawa
Author

Murtaza Ali
Author

Ron Jacob
Author

Edmond Obeng-Gyimah
Author

Michael N Vranian
Author

Clement Lau
Author

Duygu Kocyigit Burunkaya
Author

Andreas Metzner
Author

Kemal Emrecan Parsova
Author

Reshma Amin
Author

Deepti Ranganathan
Author
You may be interested in






